Scarica l'app Stockscreener
7.47
0.40%
0.03
Dopo l'orario di chiusura:
7.50
0.03
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHC Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bausch Health Companies Inc Borsa (BHC) Ultime notizie
Xifaxan selected for CMS drug price talks in 2027 - MSN
Bausch Health Companies (NYSE:BHC) Sees Strong Trading VolumeHere's Why - MarketBeat
Bausch Health acknowledges XIFAXAN selection for Medicare Negotiation Program - MSN
Xifaxan selected for CMS drug price talks in 2027 By Investing.com - Investing.com South Africa
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Statement on Selection of XIFAXAN(R)?(rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - WICZ
Bausch Health’s XIFAXAN Selected for Medicare Price Negotiation - TipRanks
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - Yahoo Finance
Topical Drugs Market Trends Analysis Report 2025-2030, with - GlobeNewswire
Topical Drugs Market Trends Analysis Report 2025-2030, with Profiles of Bayer, Cipla, GSK, Novartis, Bausch Health Companies, Hisamitsu Pharmaceuticals, Merck, Glenmark Pharmaceuticals & MedPharm - Yahoo Finance
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Innovations in Scar Treatment Market: What to Expect by 2031 | Bausch Health Companies Inc., Candela Medical - EIN News
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Average PT from Analysts - MarketBeat
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Actinic Keratosis Market Investment Opportunities: A Guide to 2031 | Almirall, S.A, Bausch Health Companies Inc. - openPR
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America - The Manila Times
George Medicines signs exclusive licensing agreement with - GlobeNewswire
Barclays PLC Cuts Position in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Is Bausch Health Companies (BHC) the Best Medical Stock to Buy Under $20? - Yahoo Finance
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Bausch Health Companies (TSE:BHC) Trading Up 3%Here's Why - MarketBeat
Here's Why Bausch Health (BHC) is a Strong Momentum Stock - Yahoo Finance
Myopia And Presbyopia Treatment Market Future Business - openPR
Botanical and Plant-Derived Drugs Market to Grow by USD 18.66 Billion (2025-2029), Driven by Government Initiatives and AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Bausch Health Companies Inc (BHC-T) QuotePress Release - The Globe and Mail
124,534 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Range Financial Group LLC - MarketBeat
Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health - Barchart
Scar Treatment Market Overall Study Report 2025-2032 | Bausch - openPR
Geode Capital Management LLC Increases Holdings in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Non-surgical Skin Tightening Market Report 2024-2029, with - GlobeNewswire
$2.5+ Bn Body Contouring Treatments MarketsGlobal Analysis and Forecasts to 2029 with AbbVie, Inmode), Bausch Health, Cynosure Lutronic, and Sisram Medical Leading - GlobeNewswire
Face Treatment Market Key Players AnalysisLutron, Bausch - openPR
BAUSCH HEALTH COMPANIES INC. DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc. (NYSE:BHC) - AccessWire
Bausch Health Companies (BHC) Shares Cross Above 200 DMA - Nasdaq
Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability - Simply Wall St
T-cell Lymphoma Market Key Players Analysis4SC AG, Acrotech - openPR
Periodontal Disease Treatment Market Dynamics and Key Trends: - openPR
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Consensus Target Price from Analysts - MarketBeat
Bausch + Lomb confirms potential sale is 'one of several options being explored' - MSN
Zacks Research Issues Optimistic Outlook for BHC Earnings - MarketBeat
FY2024 EPS Estimates for TSE:BHC Raised by Analyst - MarketBeat
Zacks Research Issues Optimistic Forecast for BHC Earnings - MarketBeat
Is Bausch Health Companies (BHC) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Yahoo Finance
Bausch Health Companies Inc. (NYSE:BHC) Stock Position Reduced by Franklin Resources Inc. - MarketBeat
Bausch Health's SWOT analysis: debt woes cloud strong q3 for diverse pharma stock - Investing.com
Canada: Bausch Health responds to rumours of potential sale of Bausch + Lomb - Investors in Healthcare
Bausch Health Companies Inc. (NYSE:BHC) Short Interest Up 9.9% in November - MarketBeat
Bausch + Lomb responds to rumors of a potential sale - The Pharma Letter
Bausch Health tanks 23.3% on unconfirmed report of bankruptcy filing - MSN
Bausch And Lomb Says Potential Sale In The Works - Law360
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):